{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:04:57Z","timestamp":1787580297106,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"DOI":"10.2146\/ajhp110559","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T06:01:30Z","timestamp":1351663290000},"page":"1872-1879","source":"Crossref","is-referenced-by-count":14,"title":["Antipsychotic treatment response in schizophrenia"],"prefix":"10.1093","volume":"69","author":[{"given":"Kristen N.","family":"Gardner","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene R.","family":"Bostwick","sequence":"additional","affiliation":[{"name":"Department of Clinical, Social, and Administrative Sciences, College of Pharmacy, University of Michigan, and Clinical Pharmacist, Adult Psychiatry, University of Michigan Health System, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041203594383600_b1-0691872","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2008.03.016","article-title":"Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders","volume":"102","author":"Agid","year":"2008","journal-title":"Schizophr Res."},{"key":"2019041203594383600_b2-0691872","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"2019041203594383600_b3-0691872","first-page":"93","article-title":"The \u201cdelayed onset\u201d of antipsychotic action\u2014an idea whose time has come and gone","volume":"31","author":"Agid","year":"2006","journal-title":"J Psychiatry Neurosci."},{"key":"2019041203594383600_b4-0691872","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1176\/appi.ajp.162.5.939","article-title":"Evidence for onset of antipsychotic effects within the first 24 hours of treatment","volume":"162","author":"Kapur","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b5-0691872","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b6-0691872","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"2019041203594383600_b7-0691872","first-page":"483","article-title":"Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder","volume":"5","author":"Bishara","year":"2009","journal-title":"Neuropsychiatr Dis Treat."},{"key":"2019041203594383600_b8-0691872","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/070674378202700305","article-title":"Comparison of pimozide and chlorpromazine in acute schizophrenia","volume":"27","author":"Pecknold","year":"1982","journal-title":"Can J Psychiatry"},{"key":"2019041203594383600_b9-0691872","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"2019041203594383600_b10-0691872","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1345\/aph.1M603","article-title":"Iloperidone for the treatment of schizophrenia","volume":"44","author":"Marino","year":"2010","journal-title":"Ann Pharmacother."},{"key":"2019041203594383600_b11-0691872","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b12-0691872","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophr Res."},{"key":"2019041203594383600_b13-0691872","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res."},{"key":"2019041203594383600_b14-0691872","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1185\/030079904125004033","article-title":"Quetiapine in schizophrenia: onset of action within the first week of treatment","volume":"20","author":"Small","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"2019041203594383600_b15-0691872","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-244X-7-4","article-title":"Early onset of treatment effects with oral risperidone","volume":"7","author":"Raedler","year":"2007","journal-title":"BMC Psychiatry"},{"key":"2019041203594383600_b16-0691872","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"2019041203594383600_b17-0691872","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"key":"2019041203594383600_b18-0691872","volume-title":"Schizophrenia manual","year":"2008"},{"key":"2019041203594383600_b19-0691872","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.schbul.a006926","article-title":"The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia","volume":"28","author":"Marder","year":"2002","journal-title":"Schizophr Bull"},{"key":"2019041203594383600_b20-0691872","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition (2004). www.guideline.gov\/content.aspx?id=5217."},{"issue":"suppl 11","key":"2019041203594383600_b21-0691872","first-page":"3","article-title":"Treatment of schizophrenia 1999","volume":"60","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b22-0691872","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended","volume":"57","author":"Leucht","year":"2005","journal-title":"Biol Psychiatry"},{"key":"2019041203594383600_b23-0691872","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/appi.ps.55.12.1444-a","article-title":"Identifying life stressors of patients with schizophrenia at hospital discharge","volume":"55","author":"Kimhy","year":"2004","journal-title":"Psychiatr Serv."},{"key":"2019041203594383600_b24-0691872","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1185\/030079907X226050","article-title":"Review and analysis of hospitalization costs associated with antipsychotic non-adherence in the treatment of schizophrenia in the United States","volume":"23","author":"Sun","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"2019041203594383600_b25-0691872","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1176\/appi.ajp.160.11.2063","article-title":"Early prediction of antipsychotic response in schizophrenia","volume":"160","author":"Correll","year":"2003","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b26-0691872","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","article-title":"Early prediction of antipsychotic nonresponse among patients with schizophrenia","volume":"68","author":"Leucht","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b27-0691872","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"2019041203594383600_b28-0691872","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b29-0691872","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.schres.2008.01.018","article-title":"Predicting antipsychotic drug response\u2014 replication and extension to six weeks in an international olanzapine study","volume":"101","author":"Leucht","year":"2008","journal-title":"Schizophr Res."},{"key":"2019041203594383600_b30-0691872","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.schres.2009.06.001","article-title":"Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods","volume":"113","author":"Chen","year":"2009","journal-title":"Schizophr Res."},{"key":"2019041203594383600_b31-0691872","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4088\/JCP.v67n1106","article-title":"Remission in first-episode psychosis: predictor variables and symptom improvement patterns","volume":"67","author":"Emsley","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b32-0691872","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jpsychires.2006.05.002","article-title":"Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables","volume":"41","author":"Crespo-Facorro","year":"2007","journal-title":"J Psychiatr Res."},{"key":"2019041203594383600_b33-0691872","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1176\/ajp.2006.163.4.743","article-title":"Time course for antipsychotic treatment response in first-episode schizophrenia","volume":"163","author":"Emsley","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b34-0691872","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.10m06349","article-title":"Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?","volume":"72","author":"Gallego","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b35-0691872","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1017\/S0033291710002035","article-title":"The different trajectories of antipsychotic response: antipsychotics versus placebo","volume":"41","author":"Marques","year":"2011","journal-title":"Psychol Med."},{"key":"2019041203594383600_b36-0691872","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b37-0691872","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2008.09.031","article-title":"Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial","volume":"107","author":"Rosenheck","year":"2009","journal-title":"Schizophr Res."},{"key":"2019041203594383600_b38-0691872","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/CEOR.S16859","article-title":"Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy","volume":"3","author":"Peng","year":"2011","journal-title":"Clinicoecon Outcomes Res."},{"issue":"suppl 1","key":"2019041203594383600_b39-0691872","first-page":"4","article-title":"Strategies for dosing and switching antipsychotics for optimal clinical management","volume":"69","author":"Buckley","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2019041203594383600_b40-0691872","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH\u2013MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"key":"2019041203594383600_b41-0691872","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b42-0691872","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1176\/appi.ajp.163.3.433","article-title":"Prognostic variables at intake and long-term level of function in schizophrenia","volume":"163","author":"Siegel","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2019041203594383600_b43-0691872","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/sbq104","article-title":"Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia","volume":"37","author":"Blanchard","year":"2011","journal-title":"Schizophr Bull"},{"key":"2019041203594383600_b44-0691872","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"2019041203594383600_b45-0691872","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.comppsych.2010.12.003","article-title":"Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia","volume":"53","author":"Liu-Seifert","year":"2012","journal-title":"Compr Psychiatry"},{"key":"2019041203594383600_b46-0691872","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ps.2010.61.12.1239","article-title":"Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics","volume":"61","author":"Lang","year":"2010","journal-title":"Psychiatr Serv."},{"key":"2019041203594383600_b47-0691872","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/schbul\/sbm061","article-title":"Outpatient antipsychotic treatment and inpatient costs of schizophrenia","volume":"34","author":"Marcus","year":"2008","journal-title":"Schizophr Bull"},{"key":"2019041203594383600_b48-0691872","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1185\/030079907X226050","article-title":"Review and analysis of hospitalization costs associated with antipsychotic non-adherence in the treatment of schizophrenia in the United States","volume":"23","author":"Sun","year":"2007","journal-title":"Curr Med Res Opin."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/21\/1872\/28361937\/ajhp1872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T23:59:49Z","timestamp":1555113589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/21\/1872\/5112027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,1]]},"references-count":48,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110559","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,11,1]]},"published":{"date-parts":[[2012,11,1]]}}}